Navigation Links
Skewered pumpkins
Date:3/7/2008

This release is available in German.

We encounter valves every day, whether in the water faucet, the carburetor in our car, or our bicycle tire tube. Valves are also present in the world of nanotechnology. A team of researchers headed by J. Fraser Stoddart and Jeffrey I. Zink at the University of California, Los Angeles, has now developed a new nanovalve. In the journal Angewandte Chemie, the scientists reveal what is special about it: In contrast to prior versions, which only function in organic solvents, this valve operates in an aqueous environment and under physiological conditionsprerequisites for any application as a gate for nanoscopic drug-transport agents, which need to set their cargo free at the right place and time.

In order for pharmaceuticals to affect only the target diseased organ, suitable nanopackaging is required to bring the drug to the target area and release it only there. One example of a good nanoscopic packaging agent is a tiny sphere of porous silica. Its pores can be filled with the drug and closed with tiny controllable valves.

The scientists attached stem-shaped molecules onto the surface of the porous spheres and filled the pores with guest molecules. At neutral to acidic pH values, they stacked cucurbituril molecules onto these stems. Cucurbituril is a fat, ring-shaped molecule reminiscent of a pumpkin that has both ends hollowed out. The resulting supramolecular structure, which resembles a skewered pumpkin and is known to chemists as a pseudorotaxane, blocks the pores, so that the guest molecules cannot exit. The nanovalve is closed.

If the pH value is raised into the basic range, however, the interaction between the pumpkins and the skewers is weakened, and the pumpkins come off, opening the pores. Now the valves are open and the guest molecules can exit.

At this point the molecular details of the individual components still need to be tweaked. The goal: very small differences in pH values between healthy and diseased tissue should be sufficient to switch the valves and release the drug only in diseased cells.


'/>"/>

Contact: Jeffrey I. Zink
zink@chem.ucla.edu
310-825-1001
Wiley-Blackwell
Source:Eurekalert  

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Skewered pumpkins
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology: